Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins.

Fazio S, Minnier J, Shapiro MD, Tsimikas S, Tarugi P, Averna MR, Arca M, Tavori H

Application of PCSK9 Inhibitors in Practice: Challenges and Opportunities.

Kaufman TM, Duell PB, Purnell JQ, Wójcik C, Fazio S, Shapiro MD

Setting the Agenda for Preventive Cardiology.

Shapiro MD, Fazio S

Pigeonetics takes flight: Evolution, development, and genetics of intraspecific variation.

Domyan ET, Shapiro MD

Dyslipidaemia: The PCSK9 adventure - humanizing extreme LDL lowering.

Shapiro MD, Fazio S

Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.

Edmiston JB, Brooks N, Tavori H, Minnier J, Duell B, Purnell JQ, Kaufman T, Wojcik C, Voros S, Fazio S, Shapiro MD

PCSK9 and Atherosclerosis - Lipids and Beyond.

Shapiro MD, Fazio S

Mutation-negative" familial hypercholesterolemia-When negative is positive.

Shapiro MD

Normative Data for a Comprehensive Neuropsychological Test Battery used in the Assessment of Sports-Related Concussion.

Merritt VC, Meyer JE, Cadden MH, Roman CA, Ukueberuwa DM, Shapiro MD, Arnett PA

Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease.

Shapiro MD, Fazio S